Adherence to Iron Chelation Therapy and Its Determinants

Adherence to Iron Chelation Therapy and Its Determinants

Background: Thalassemia is a chronic disease requiring lifelong treatment. The adherence to regular iron chelation therapy is important to ensure complication-free survival and good quality of life. The study aim to assess the adherence to iron chelation therapy (ICT) in patients with transfusion...

Full description

Bibliographic Details
Main Authors:	Sukhmani Sidhu, Shruti Kakkar, Priyanka Dewan, Namita Bansal, Praveen C. Sobti
Format:	Article
Language:	English
Published:	Tehran University of Medical Sciences 2021-01-01
Series:	International Journal of Hematology-Oncology and Stem Cell Research
Subjects:	Adherence; Iron chelation therapy; Iron overload; Transfusion dependent thalassemia; Deferiprone; Deferasirox; Desferrioxamine
Online Access:	https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1262

Similar Items

Iron Chelator Drugs in Transfusion Dependent Thalassemia: a Review
by: M Hashemieh
Published: (2020-08-01)

Recent developments centered on orally active iron chelators
by: Robert Hider
Published: (2014-09-01)

IRON CHELATION THERAPY IN THALASSEMIA SYNDROMES
by: Paolo Cianciulli
Published: (2009-06-01)

Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives
by: Bayanzay K, et al.
Published: (2016-08-01)

Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusiondependent β-thalassemia major
by: Hossein Karami, et al.
Published: (2017-01-01)

Home isolation in transfusion-dependent thalassemia patients with SARS CoV2 infection: Experience from a developing country
by: Shruti Kakkar, et al.
Published: (2022-09-01)

Terapia quelante oral com deferiprona em pacientes com sobrecarga de ferro Oral iron chelator therapy with deferiprone in patients with overloaded iron
by: Antonio Fabron Jr, et al.
Published: (2003-01-01)

LONG-TERM EFFECTIVENESS, SAFETY, AND TOLERABILITY OF TWICE-DAILY DOSING WITH DEFERASIROX IN CHILDREN WITH TRANSFUSION-DEPENDENT THALASSEMIAS UNRESPONSIVE TO STANDARD ONCE-DAILY DOSING
by: Jassada Buaboonnam, et al.
Published: (2021-10-01)

Barriers to adherence to iron chelation therapy among adolescent with transfusion dependent thalassemia
by: Rafaa Mohamed, et al.
Published: (2022-10-01)

Development of Thalassemia Medication Questionnaire (TMQ): An Instrument for Measuring Major Thalassemia Patients’ Knowledge and Practice Regarding their Medications
by: Azita Azarkeivan, et al.
Published: (2022-12-01)

Sex and Gender Differences in Iron Chelation
by: Sarah Allegra, et al.
Published: (2024-12-01)

Sobrecarga e quelação de ferro na anemia falciforme Iron overload and iron chelation in sickle cell disease
by: Rodolfo D. Cançado
Published: (2007-09-01)

Challenges of Iron Chelation in Thalassemic Children
by: Alkistis Adramerina, et al.
Published: (2024-02-01)

DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
by: Ali Taher
Published: (2018-11-01)

Combination therapies in iron chelation
by: Raffaella Origa
Published: (2014-12-01)

Dutch-beta thalassemia: A rare mutation from India
by: Nirali Sanghvi, et al.
Published: (2022-09-01)

Use of Deferasirox Film-Coated Tablets in Pediatric Patients with Transfusion Dependent Thalassemia: A Single Center Experience
by: Alkistis Adramerina, et al.
Published: (2022-02-01)

Chelation Combination—A Strategy to Mitigate the Neurotoxicity of Manganese, Iron, and Copper?
by: Jan O. Aaseth, et al.
Published: (2022-11-01)

Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes [version 2; peer review: 2 approved]
by: Khairunnisa Khairunnisa, et al.
Published: (2023-12-01)

Multiple transfused thalassemia major: Ocular manifestations in a hospital-based population
by: Taneja Rashi, et al.
Published: (2010-01-01)

Kidney Tubular Damage Secondary to Deferasirox: Systematic Literature Review
by: Martin Scoglio, et al.
Published: (2021-12-01)

Knowledge, Attitude, and Practice of Young Paediatricians About Chelation Therapyin Transfusion-Dependent Thalassemia Major Children
by: Misbah Fakih, et al.
Published: (2022-12-01)

Assessment of the effect of combination therapy with Deferiprone & Desferrioxamine on cardiac complications in major Thalassemia
by: F. Rashidi ghader, M.D, et al.
Published: (2007-01-01)

Antioxidant Activity of Deferasirox and Its Metal Complexes in Model Systems of Oxidative Damage: Comparison with Deferiprone
by: Viktor A. Timoshnikov, et al.
Published: (2021-08-01)

Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine
by: Mohamed Abdel Malik Hassan, et al.
Published: (2016-05-01)

Comparative study of efficacy of different iron chelating agents in treatment of iron overload in children with Beta Thalassemia Major
by: adel abd elhaleim hagag
Published: (2014-08-01)

IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS
by: Elena Maria Elli, et al.
Published: (2014-05-01)

Iron and Acinetobacter baumannii Biofilm Formation
by: Valentina Gentile, et al.
Published: (2014-08-01)

Comparative analysis of deferasirox and deferiprone iron chelator on the growth pattern of Bengali β-thalassemia major children of West Bengal, India
by: Isita Tripathy, et al.
Published: (2022-09-01)

BETA THALASSEMIA MAJOR IN A DEVELOPING COUNTRY: EPIDEMIOLOGICAL, CLINICAL AND EVOLUTIONARY ASPECT
by: Mohamed Bejaoui, et al.
Published: (2013-01-01)

Markers of Renal Complications in Beta Thalassemia Patients with Iron Overload Receiving Chelation Agent Therapy: A Systematic Review
by: Romadhon PZ, et al.
Published: (2022-11-01)

The COST-UTILITY ANALYSIS OF FOUR CHELATION REGIMENS FOR Β-THALASSEMIA MAJOR: A CHINESE PERSPECTIVE
by: Jialian Li
Published: (2020-04-01)

Synthesis of Deferiprone as a Widely Used Iron-Chelating Drug for the Treatment of Iron-Overload Diseases
by: Sara Sadeghian, et al.
Published: (2024-03-01)

Comparative efficacy, safety, and cost of iron chelation monotherapy vs. combination therapy in pediatric beta-thalassemia major: a single-center retrospective study
by: Dewi Sharon Simorangkir, et al.
Published: (2022-03-01)

Comparison of the effects of deferasirox film-coated tablets (Jadenu®) and deferasirox dispersible tablets (Exjade®) in patients with beta thalassemia major: a preliminary report of the effects on the satisfaction, convenience, cardiac/liver MRI T2*, serum ferritin level, and biochemical profiles
by: Mahya Mobinikhaledi, et al.
Published: (2024-11-01)

Addressing adherence to treatment: a longstanding concern. The patients’ perspective
by: Mahmoud Hadipour Dehshal
Published: (2014-12-01)

Iron-chelating and anti-lipid peroxidation properties of 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one (CM1) in long-term iron loading β-thalassemic mice
by: Kanokwan Kulprachakarn, et al.
Published: (2014-08-01)

A cross-sectional study of awareness and practices regarding thalassemia among parents of thalassemic children
by: Ankur Jain, et al.
Published: (2020-01-01)

The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases
by: George J. Kontoghiorghes
Published: (2023-07-01)

ECONOMIC EVALUATION OF CHELATION REGIMENS FOR β--THALASSEMIA MAJOR: A SYSTEMATIC REVIEW
by: Jialian Li
Published: (2019-06-01)